AXGN - アクソジェン (AxoGen Inc.) アクソジェン



symbol AXGN
会社名 AxoGen Inc (アクソジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アクソーゲン(AxoGen Inc.)は末梢神経損傷に対する外科的ソリューションを提供する。同社は末梢神経損傷の外科治療アルゴリズムを改善するための製品と教育を提供する。製品ポートフォリオには、アバンス神経移植片、AxoGuard神経コネクター、AxoGuard神経プロテクター及びAvive軟組織膜を含む。同社はこれらの中核外科用製品とともに、AxoTouch 2点識別器、AcroVal神経感知器及びモータ検査システムを提供する。評価及び測定ツールは医療従事者が感覚変化の検出、感覚・握り・つまみ機能の回復の評価、治療介入の評価、神経機能関連の患者へのフィードバックの提供を支援する。同社の製品ポートフォリオは、米国、カナダ、英国とヨーロッパ及びその他の国に利用できる。同社の製品は外科医が外科的介入中に身体全体の神経損傷を修復するために使用される。   アクソジェンは、米国の再生医療会社。 末梢神経再建および再生技術の開発と商品化に従事。同社の製品は、末梢神経の修復のために使用される。主な製品は、神経移植片「アバンス」や末端神経の保護・再生用生体素材「アクソガ―ド」など。本社は、フロリダ州アラチュア。   Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
本社所在地 13631 Progress Blvd. Suite 400 Alachua FL 32615 USA
代表者氏名 Karen L. Zaderej カレン・L・ザデレージ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 386-462-6817
設立年月日 1977年
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 199人
EBITDA EBITDA(百万ドル) -12.39234
終値(lastsale) 34.9
時価総額(marketcap) 1337474305.4
時価総額 時価総額(百万ドル) 1315.247
売上高 売上高(百万ドル) 70.86162
企業価値(EV) 企業価値(EV)(百万ドル) 1181.76897
当期純利益 当期純利益(百万ドル) -17.68912
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AxoGen Inc revenues increased 38% to $37.8M. Net loss increased from $5.8M to $13.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Sales and marketing increase of 47% to $25.7M (expense) General and administrative increase of 55% to $10.7M (expense).



   AxoGen, Inc. (NASDAQ:AXGN) Shares Sold by Assenagon Asset Management S.A.  2021/12/06 11:00:43 Dakota Financial News
Assenagon Asset Management S.A. lessened its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 24.7% in the 3rd quarter, Holdings reports. The firm owned 387,524 shares of the medical equipment provider’s stock after selling 127,253 shares during the quarter. Assenagon Asset Management S.A.’s holdings in AxoGen were worth $6,123,000 as of its most recent […]
   AxoGen, Inc. (NASDAQ:AXGN) Shares Sold by Cubist Systematic Strategies LLC  2021/12/02 09:48:41 Dakota Financial News
Cubist Systematic Strategies LLC lowered its stake in AxoGen, Inc. (NASDAQ:AXGN) by 29.8% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,058 shares of the medical equipment providers stock after selling 2,143 shares during the quarter. Cubist Systematic Strategies LLCs holdings in AxoGen []
   Exchange Traded Concepts LLC Has $3.27 Million Stock Position in AxoGen, Inc. (NASDAQ:AXGN)  2021/12/01 13:22:42 Transcript Daily
Exchange Traded Concepts LLC lifted its position in AxoGen, Inc. (NASDAQ:AXGN) by 21.5% in the third quarter, Holdings reports. The institutional investor owned 206,695 shares of the medical equipment providers stock after buying an additional 36,566 shares during the period. Exchange Traded Concepts LLCs holdings in AxoGen were worth $3,266,000 at the end of []
   Nerve Conduit Market By Product and Service, By Application, By End User and Region: Global Industry Analysis, Share, Opportunity, Competition and Forecast 2021 to 2027 - Synovis, Polyganics, Collagen Matrix, Stryker, Axogen  2021/11/29 04:25:34 OpenPR
The Nerve Conduit Market report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an
   Axogen Inc. Shares Close in on 52-Week Low - Market Mover  2021/11/27 13:07:10 Kwhen Finance
Axogen Inc. (AXGN) shares closed today at 0.9% above its 52 week low of $9.50, giving the company a market cap of $398M. The stock is currently down 46.4% year-to-date, down 32.8% over the past 12 months, and up 9.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 41.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -440.8% The company's stock price performance over the past 12 months lags the peer average by -270.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at Write to © 2020 Kwhen Inc.
   Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand  2021/09/22 11:00:00 Intrado Digital Media
Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during symposium session
   Neurostimulation and Neuromodulation Device Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027 | Axogen, Baxter, Boston Scientific, Livanova, Integra Lifesciences, Medtronic, Abbott Laboratories, Stryker, PolyganicS  2021/09/20 05:03:39 OpenPR
The Neurostimulation and Neuromodulation Device Market provides analysis and insights relating to the many factors expected to be rife throughout the forecast amount whereas providing their impacts on the Markets growth. The increase within the aviation sector is escalating the
   AxoGen, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/16 19:18:19 Seeking Alpha
   BioFlorida Announces Five New Board Members  2021/08/11 14:03:00 Benzinga
WEST PALM BEACH, Fla. , Aug. 11, 2021 /PRNewswire/ -- BioFlorida has announced five new board members who will support the organization''s effort to grow the life sciences industry in Florida . "The life sciences industry in Florida is vibrant, and we''re excited to welcome Thomas Equels of AIM ImmunoTech, Mark Friedman , PhD of Axogen, Geoff Green of Longeveron, Adam Grossman of ADMA Biologics, and Joe Sardano of Sensus Healthcare," said Nancy Bryan , President and CEO of BioFlorida. "Our new board members are leaders in their fields with a passion to unite with our diverse Board of Directors representing the various sectors and regions in Florida with a collective goal to advance the impressive, diverse life sciences ecosystem." Today, the life sciences industry in the state represents 6,700 establishments and research organizations in biopharmaceuticals, medical technology, healthIT and bioagriculture that collectively employ nearly 94,000 Floridians "BioFlorida provides Florida''s life sciences industry with a venue to collaborate to address global health challenges," said Rob Herzog , Chair of the BioFlorida Board and Vice President of Research and Operations at Advent Health. "I look forward to working with our new board members to continue to build Florida as a life sciences destination." The new board members began their two-year term on January 1, 2021 .
   Axogen Inc (AXGN) CEO Karen L. Zaderej Sold $757,270 of Shares  2021/08/11 02:15:08 GuruFocus
Related Stocks: AXGN ,
   Nerve Repair and Re-generation Biomaterials Market to Witness Astonishing Growth by 2027 | Axogen, Integra, Synovis  2021/07/18 17:11:24 Tramways Monthly
Nerve Repair and Re-generation Biomaterials Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied []
   Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021  2021/07/14 11:00:00 Intrado Digital Media
ALACHUA, Fla. and TAMPA, Fla., July 14, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
   Tissue Growth: Axogens Biologic Transition Leads to Expansion  2021/06/25 01:41:08 Genetic Engineering & Biotechnology News
Axogen plans to process only human nerve tissue for Avance and other products at the new facility, which is being built to cGMP standards, and is intended to support a future Biologics License Application (BLA) for Avance Nerve Graft to the FDA. The post Tissue Growth: Axogens Biologic Transition Leads to Expansion appeared first on GEN - Genetic Engineering and Biotechnology News .
   Meet Pete Mariani, a 2021 CFO of the Year honoree  2021/06/01 13:40:52 Business Journals
Peter Mariani is the executive vice president and chief financial officer of Axogen.
   AxoGen (AXGN) Receives a Buy from Leerink Partners  2021/05/31 07:59:07 Smarter Analyst
In a report issued on May 26, Richard Newitter from Leerink Partners maintained a Buy rating on AxoGen (AXGN), with a price target The post AxoGen (AXGN) Receives a Buy from Leerink Partners appeared first on Smarter Analyst .

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アクソジェン AXGN AxoGen Inc.)


 twitter  (公式ツイッターやCEOツイッターなど)